---
title: "Urologic cancer risk after hospital-diagnosed recurrent cystitis: nationwide cohort analysis"
id: "british-journal-of-cancer-0-risk-of-urologic-cancers-in-patients-with-hospital-diagnosed-recurrent-cystitis"
canonical_url: "https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-risk-of-urologic-cancers-in-patients-with-hospital-diagnosed-recurrent-cystitis"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "British Journal of Cancer"
source_url: "https://www.nature.com/articles/s41416-026-03591-y"
published_at: "2026-08-19T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Urologic cancer risk after hospital-diagnosed recurrent cystitis: nationwide cohort analysis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-risk-of-urologic-cancers-in-patients-with-hospital-diagnosed-recurrent-cystitis
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** British Journal of Cancer
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41416-026-03591-y)
- **Published At:** 2026-08-19T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This nationwide population-based cohort study included all Danish adults with a first-time hospital discharge diagnosis of **recurrent cystitis** from 2006–2022, excluding those with prior cancer. - Among 42,377 patients (68% women, median age 62 years) followed for a median of 5.7 years, 1,047 were diagnosed with a **urologic cancer**. - The 1-year absolute risk of any urologic cancer after recurrent cystitis was 1.2% (95% CI, 1.1–1.3%). - The 1-year standardized incidence ratio (SIR) for any urologic cancer was markedly elevated at 4.99 (95% CI, 4.56–5.44), indicating a large short-term relative increase compared with the general population. - Beyond two years of follow-up, the overall SIR declined; a persistent elevated long-term SIR was observed **only among women** (SIR 1.47, 95% CI, 1.20–1.78). - Authors interpret the pronounced short-term rise in cancer diagnoses as suggesting that recurrent cystitis can serve as a **clinical marker** for underlying urologic cancer, while noting low absolute risks that do not warrant routine extra diagnostic work-up. - The article situates findings in the context of prior literature: UTIs and recurrent UTIs have been variably associated with bladder and other urologic cancers, with heterogeneity across studies and possible confounding by shared risk factors such as smoking and obesity. - The study used validated national registries: recurrent cystitis from the Danish National Patient Registry and cancer outcomes from the Danish Cancer Registry; specific methodological details beyond this summary were not included in the provided source text. - The authors note possible mechanisms (chronic inflammation promoting carcinogenesis) and alternative explanations such as symptom overlap and detection bias explaining the short-term increase; precise subgroup and sensitivity analysis results were not reported in the extracted source material.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41416-026-03591-y#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![British Journal of Cancer](https://media.springernature.com/full/nature-cms/uploads/product/bjc/header-76ac17391903a21e28f15ff5df31f5fa.svg) ](https://www.nature.com/bjc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41416-026-03591-y) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/bjc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/bjc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/bjc/news-and-comment) * [ Current issue ](https://www.nature.com/bjc/current-issue) * [ Collections ](https://www.nature.com/bjc/collections) * [Follow us on X ](https://twitter.com/BrJCancer) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Journal Information ](https://www.nature.com/bjc/journal-information) * [ Open access publishing ](https://www.nature.com/bjc/open-access) * [ About the Editors ](https://www.nature.com/bjc/editors) * [ Contact ](https://www.nature.com/bjc/contact) * [ Special Issues ](https://www.nature.com/bjc/special-issues) * [ For Advertisers ](https://www.nature.com/bjc/advertising) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors & Referees ](https://www.nature.com/bjc/authors-and-referees) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/bjc/open-access-funding) * [Submit manuscript ](https://mts-bjcancer.nature.com/) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) 1. [nature](https://www.nature.com/) 2. [british journal of cancer](https://www.nature.com/bjc) 3. [articles](https://www.nature.com/bjc/articles?type=article) 4. article Risk of urologic cancers in patients with hospital-diagnosed recurrent cystitis: a nationwide population-based study [ Download PDF ](https://www.nature.com/articles/s41416-026-03591-y.pdf) [ Download PDF ](https://www.nature.com/articles/s41416-026-03591-y.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 19 August 2026 Epidemiology # Risk of urologic cancers in patients with hospital-diagnosed recurrent cystitis: a nationwide population-based study * [Kasper Kjersgaard Mortensen](https://www.nature.com/articles/s41416-026-03591-y#auth-Kasper_Kjersgaard-Mortensen-Aff1) [ORCID: orcid.org/0000-0003-1965-0268](https://orcid.org/0000-0003-1965-0268)[1](https://www.nature.com/articles/s41416-026-03591-y#Aff1), * [Kirstine Kobberøe Søgaard](https://www.nature.com/articles/s41416-026-03591-y#auth-Kirstine_Kobber_e-S_gaard-Aff1-Aff2)[1](https://www.nature.com/articles/s41416-026-03591-y#Aff1),[2](https://www.nature.com/articles/s41416-026-03591-y#Aff2), * [Dóra Körmendiné Farkas](https://www.nature.com/articles/s41416-026-03591-y#auth-D_ra_K_rmendin_-Farkas-Aff1)[1](https://www.nature.com/articles/s41416-026-03591-y#Aff1), * [Eyal Oren](https://www.nature.com/articles/s41416-026-03591-y#auth-Eyal-Oren-Aff1-Aff3)[1](https://www.nature.com/articles/s41416-026-03591-y#Aff1),[3](https://www.nature.com/articles/s41416-026-03591-y#Aff3), * [Mette Nørgaard](https://www.nature.com/articles/s41416-026-03591-y#auth-Mette-N_rgaard-Aff1) [ORCID: orcid.org/0000-0001-6110-5891](https://orcid.org/0000-0001-6110-5891)[1](https://www.nature.com/articles/s41416-026-03591-y#Aff1) & * … * [Henrik Toft Sørensen](https://www.nature.com/articles/s41416-026-03591-y#auth-Henrik_Toft-S_rensen-Aff1) [ORCID: orcid.org/0000-0003-4299-7040](https://orcid.org/0000-0003-4299-7040)[1](https://www.nature.com/articles/s41416-026-03591-y#Aff1) Show authors [_British Journal of Cancer_](https://www.nature.com/bjc) (2026) [Cite this article](https://www.nature.com/articles/s41416-026-03591-y#citeas) [ Save article ](https://www.nature.com/articles/s41416-026-03591-y/save-research?_csrf=xlT1LRRSlFSsn9WH1TKWEXwWfyOpnCXZ) [ View saved research ](https://www.nature.com/saved-research) ## Abstract ### Background Recurrent infections in the urinary tract may promote urologic cancer through chronic inflammation. However, evidence linking infections and the subsequent risk of urologic cancer has been conflicting, and long-term risk remains uncertain. ### Methods In this population-based descriptive cohort study, we included all Danish adults with a first-time hospital discharge diagnosis of recurrent cystitis during 2006–2022 in the Danish National Patient Registry, excluding patients with prior cancer. Urologic cancer diagnoses were ascertained through the Danish Cancer Registry. We calculated cumulative incidences and standardised incidence ratios (SIRs) using incidence rates from the general population. ### Results Among 42,377 patients (68% women, median age 62 years), 1047 were diagnosed with urologic cancer (median follow-up 5.7 years). The 1-year risk of any urologic cancer was 1.2% (95% confidence interval [CI], 1.1–1.3%). The corresponding 1-year SIR was 4.99 (95% CI, 4.56–5.44). Beyond 2 years of follow-up, the SIR remained elevated among women only at 1.47 (95% CI, 1.20–1.78). ### Conclusions The elevated short-term risk suggests that recurrent cystitis is a clinical marker of urologic cancer. Yet, with low absolute risks, our results do not suggest additional diagnostic cancer work-up in these patients. In women, long-term risks for urologic cancer remained elevated. ## Introduction Urinary tract infection (UTI) encompasses infections in the bladder, ureters, and kidneys. Half of all women and nearly 15% of men experience at least one UTI during their lifetime, and recurrence within a year is frequent (approximately 30%-50% for women and 12% for men) [[1](https://www.nature.com/articles/s41416-026-03591-y#ref-CR1 "Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in men. J Urol. 2005;173:1288–94."), [2](https://www.nature.com/articles/s41416-026-03591-y#ref-CR2 "Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1–13.")]. Worldwide, more than 2.5 million people are diagnosed annually with a urologic cancer (urinary bladder, kidney, ureteral and renal pelvic and prostate cancer), and this number is expected to increase as populations age [[3](https://www.nature.com/articles/s41416-026-03591-y#ref-CR3 "Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L, et al. Global cancer observatory: cancer tomorrow \(version 1.1\). Lyon, France: International Agency for Research on Cancer \[Internet\]; 2024. Lyon, France; 2024 \[cited 2024 Dec 11\]. https://gco.iarc.who.int/tomorrow . Accessed 11 Dec 2024.")]. These cancers are associated with both substantial morbidity and mortality [[4](https://www.nature.com/articles/s41416-026-03591-y#ref-CR4 "Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63."),[5](https://www.nature.com/articles/s41416-026-03591-y#ref-CR5 "Nørgaard M, Mailhac A, Fagerlund K, Strunz-McKendry T, Agerbæk M, Jensen JB. Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015–2020. Acta Oncol. 2023;62:1784–90."),[6](https://www.nature.com/articles/s41416-026-03591-y#ref-CR6 "Sundaram M, Song Y, Rogerio JW, Zhang S, Bhattacharya R, Adejoro O, et al. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: a retrospective analysis of Surveillance, Epidemiology, and End Results–Medicare data. J Manag Care Spec Pharm. 2022;28:1149–60.")]. Several studies have shown an elevated risk of urologic cancer among patients with UTIs [[7](https://www.nature.com/articles/s41416-026-03591-y#ref-CR7 "Søgaard KK, Veres K, Nørgaard M, Djurhuus JC, Sørensen HT. Pyelonephritis in persons after age 50 as a clinical marker of urogenital cancer. Clin Microbiol Infect. 2019;25:87–91."),[8](https://www.nature.com/articles/s41416-026-03591-y#ref-CR8 "Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP. History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol. 2004;159:42–8."),[9](https://www.nature.com/articles/s41416-026-03591-y#ref-CR9 "Fan C-Y, Huang W-Y, Lin K-T, Lin C-S, Chao H-L, Yang J-F, et al. Lower urinary tract infection and subsequent risk of prostate cancer: a nationwide population-based cohort study. PLoS ONE. 2017;12:e0168254."),[10](https://www.nature.com/articles/s41416-026-03591-y#ref-CR10 "Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 1993;4:101–10."),[11](https://www.nature.com/articles/s41416-026-03591-y#ref-CR11 "McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JF. A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst. 1984;72:275–84."),[12](https://www.nature.com/articles/s41416-026-03591-y#ref-CR12 "Sun L, Lin C, Liang J, Liu S, Sung F, Chang Y, et al. Urinary tract infection increases subsequent urinary tract cancer risk: a population-based cohort study. Cancer Sci. 2013;104:619–23."),[13](https://www.nature.com/articles/s41416-026-03591-y#ref-CR13 "Vermeulen SH, Hanum N, Grotenhuis AJ, Castaño-Vinyals G, Van Der Heijden AG, Aben KK, et al. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer. 2015;112:594–600.")]. The development of urologic cancer is multifactorial and shares several risk factors with infections, including smoking and obesity [[14](https://www.nature.com/articles/s41416-026-03591-y#ref-CR14 "Kjerulff B, Kaspersen KA, Dinh KM, Boldsen J, Mikkelsen S, Erikstrup LT, et al. Smoking is associated with infection risk in healthy blood donors. Clin Microbiol Infect. 2023;29:506–14."),[15](https://www.nature.com/articles/s41416-026-03591-y#ref-CR15 "Papavasileiou G, Tsilingiris D, Spyrou N, Vallianou NG, Karampela I, Magkos F, et al. Obesity and main urologic cancers: current systematic evidence, novel biological mechanisms, perspectives and challenges. Semin Cancer Biol. 2023;91:70–98."),[16](https://www.nature.com/articles/s41416-026-03591-y#ref-CR16 "Pugliese G, Liccardi A, Graziadio C, Barrea L, Muscogiuri G, Colao A. Obesity and infectious diseases: pathophysiology and epidemiology of a double pandemic condition. Int J Obes. 2022;46:449–65."),[17](https://www.nature.com/articles/s41416-026-03591-y#ref-CR17 "Kumar R, Matulewicz R, Mari A, Moschini M, Ghodoussipour S, Pradere B, et al. Impact of smoking on urologic cancers: a snapshot of current evidence. World J Urol. 2023;41:1473–9.")]. While chronic inflammation from recurrent infections may promote carcinogenesis [[18](https://www.nature.com/articles/s41416-026-03591-y#ref-CR18 "Lax AJ, Thomas W. How bacteria could cause cancer: one step at a time. Trends Microbiol. 2002;10:293–9."),[19](https://www.nature.com/articles/s41416-026-03591-y#ref-CR19 "Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5:749–59."),[20](https://www.nature.com/articles/s41416-026-03591-y#ref-CR20 "Nesi G, Nobili S, Cai T, Caini S, Santi R. Chronic inflammation in urothelial bladder cancer. Virchows Arch. 2015;467:623–33.")], the association between UTI-related inflammation and risk of bladder cancer is not clear [[12](https://www.nature.com/articles/s41416-026-03591-y#ref-CR12 "Sun L, Lin C, Liang J, Liu S, Sung F, Chang Y, et al. Urinary tract infection increases subsequent urinary tract cancer risk: a population-based cohort study. Cancer Sci. 2013;104:619–23."), [13](https://www.nature.com/articles/s41416-026-03591-y#ref-CR13 "Vermeulen SH, Hanum N, Grotenhuis AJ, Castaño-Vinyals G, Van Der Heijden AG, Aben KK, et al. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer. 2015;112:594–600."), [21](https://www.nature.com/articles/s41416-026-03591-y#ref-CR21 "Jiang X, Castelao JE, Groshen S, Cortessis VK, Shibata D, Conti DV, et al. Urinary tract infections and reduced risk of bladder cancer in Los Angeles. Br J Cancer. 2009;100:834–9."), [22](https://www.nature.com/articles/s41416-026-03591-y#ref-CR22 "Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JF. Urinary tract infection and risk of bladder cancer. Am J Epidemiol. 1984;119:510–5.")]. Two meta-analyses, based mainly on case-control studies, reported an association between recurrent UTI (rUTI) and elevated bladder cancer risk, but highlighted substantial between-study heterogeneity and inconsistent control of confounders [[23](https://www.nature.com/articles/s41416-026-03591-y#ref-CR23 "Akhtar S, Al-Shammari A, Al-Abkal J. Chronic urinary tract infection and bladder carcinoma risk: a meta-analysis of case–control and cohort studies. World J Urol. 2018;36:839–48."), [24](https://www.nature.com/articles/s41416-026-03591-y#ref-CR24 "Bayne CE, Farah D, Herbst KW, Hsieh MH. Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis. World J Urol. 2018;36:1181–90.")]. Associations between UTI and other urologic cancers have been less extensively studied [[8](https://www.nature.com/articles/s41416-026-03591-y#ref-CR8 "Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP. History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol. 2004;159:42–8."),[9](https://www.nature.com/articles/s41416-026-03591-y#ref-CR9 "Fan C-Y, Huang W-Y, Lin K-T, Lin C-S, Chao H-L, Yang J-F, et al. Lower urinary tract infection and subsequent risk of prostate cancer: a nationwide population-based cohort study. PLoS ONE. 2017;12:e0168254."),[10](https://www.nature.com/articles/s41416-026-03591-y#ref-CR10 "Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 1993;4:101–10."), [12](https://www.nature.com/articles/s41416-026-03591-y#ref-CR12 "Sun L, Lin C, Liang J, Liu S, Sung F, Chang Y, et al. Urinary tract infection increases subsequent urinary tract cancer risk: a population-based cohort study. Cancer Sci. 2013;104:619–23."), [25](https://www.nature.com/articles/s41416-026-03591-y#ref-CR25 "McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control. 1992;3:323–31."),[26](https://www.nature.com/articles/s41416-026-03591-y#ref-CR26 "Schlehofer B, Pommer W, Mellemgaard A, Stewart JH, McCredie M, Niwa S, et al. International renal-cell-cancer study. VI. The role of medical and family history. Int J Cancer. 1996;66:723–6."),[27](https://www.nature.com/articles/s41416-026-03591-y#ref-CR27 "Talamini R, Barón AE, Barra S, Bidoli E, La Vecchia C, Negri E, et al. A case-control study of risk factor for renal cell cancer in northern Italy. Cancer Causes Control. 1990;1:125–31."),[28](https://www.nature.com/articles/s41416-026-03591-y#ref-CR28 "Pelucchi C, Talamini R, Negri E, Franceschi S, Vecchia CL. Genital and urinary tract diseases and prostate cancer risk. Eur J Cancer Prev. 2006;15:254.")], with some studies suggesting increased risks of kidney, ureteral, renal pelvic and prostate cancer [[8](https://www.nature.com/articles/s41416-026-03591-y#ref-CR8 "Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP. History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol. 2004;159:42–8."),[9](https://www.nature.com/articles/s41416-026-03591-y#ref-CR9 "Fan C-Y, Huang W-Y, Lin K-T, Lin C-S, Chao H-L, Yang J-F, et al. Lower urinary tract infection and subsequent risk of prostate cancer: a nationwide population-based cohort study. PLoS ONE. 2017;12:e0168254."),[10](https://www.nature.com/articles/s41416-026-03591-y#ref-CR10 "Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control. 1993;4:101–10."),[11](https://www.nature.com/articles/s41416-026-03591-y#ref-CR11 "McLaughlin JK, Mandel JS, Blot WJ, Schuman LM, Mehl ES, Fraumeni JF. A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst. 1984;72:275–84.")]. Recent population-based nationwide studies from Denmark and Sweden have demonstrated a dose-response-dependent association between UTIs and a rare subtype of bladder cancer [[29](https://www.nature.com/articles/s41416-026-03591-y#ref-CR29 "Pottegård A, Kristensen KB, Friis S, Hallas J, Jensen JB, Nørgaard M. Urinary tract infections and risk of squamous cell carcinoma bladder cancer: a Danish nationwide case–control study. Int J Cancer. 2020;146:1930–6.")]. The Swedish study further reported a substantially elevated short-term risk of all urologic cancers, as well as a more modest increase in the long-term risks of certain urologic cancers following acute cystitis [[30](https://www.nature.com/articles/s41416-026-03591-y#ref-CR30 "Jansåker F, Li X, Sundquist K. Acute cystitis and subsequent risk of urogenital cancer: a national cohort study from Sweden. BMJ Public Health. 2025;3:e002495.")]. The observed short-term risk may, however, partly reflect a misinterpretation of symptoms, as there is a considerable overlap in the clinic
## Related Clinical Research

- [Stopping Statins at Age 75 in Low‑Risk Adults: French Trial Found No Increase in Deaths](https://medichelpline.com/clinical-feed/stat-news-0-stopping-statins-in-people-over-75-at-low-risk-for-heart-disease-didn-t.md)
- [Social Determinants of Health and Cardiovascular Risk in Breast and Prostate Cancer](https://medichelpline.com/clinical-feed/pubmed-43031355.md) (DOI: 10.1002/cncr.70674)
- [American Cancer Society now recommends biennial PSA screening for men 50–69](https://medichelpline.com/clinical-feed/stat-news-0-experts-update-prostate-cancer-screening-guidelines-for-men.md)
- [Long-term fatigue dimensions after radiotherapy in non-metastatic prostate cancer: MFI trajectorie](https://medichelpline.com/clinical-feed/british-journal-of-cancer-1-long-term-fatigue-dimensions-in-the-multidimensional-fatigue-inventory-mfi-up.md)
- [Dietary and Lifestyle Quality Linked to Endometrial Cancer Risk and Survivorship Outcomes](https://medichelpline.com/clinical-feed/plos-one-17-dietary-and-lifestyle-quality-and-endometrial-cancer-incidence-and-survivorship.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.